Vanda Pharmaceuticals Inc

VNDA remains in a sustained Stage 4 decline with a clear sequence of lower highs and lower lows and a primary Support Failure pattern. Volume expansion on down moves and declining EMAs confirm medium-term bearish permission, but extreme oversold readings and extended price below sloping EMAs argue against immediate selling. Under a Speculative mandate, we defer entry until a reaction rally into the falling 9/21 EMAs offers a disciplined shorting opportunity in the resistance zone.

• ↑Q1 revenue $51.7M up 3% YoY, led by FNAP +26%
• ↑2026 revenue guidance raised to $240–$290M
• ↓Net loss $48.6M in Q1 vs. $29.5M prior year, driven by SG&A rise